Navigation Links
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Date:3/12/2009

trial demonstrated the following key results:

  • A zero percent rate of stent thrombosis (blood clot formation) for all patients out to two years of follow up.
  • No new major adverse cardiac events (MACE) between six months and two years. At two years, the bioabsorbable device demonstrated a MACE rate of 3.6 percent (one patient). MACE is defined as any event that resulted in re-treatment of the treated artery lesion, heart attack or cardiac death.
  • Bioabsorption of the stent at two years after implantation, as confirmed by an assessment of the stent struts using optical coherence tomography (OCT).
  • Restoration of vasomotion (ability of the blood vessel to contract and expand) was observed at two years, with the drug acetylcholine used in nine patients showing vasodilation in the previously stented area, and the drug methergin used in seven patients showing vasoconstriction in the previously stented area.
  • Reduction in plaque area in treated arteries, corresponding to an increase in blood flow between six months and two years, as confirmed by intravascular ultrasound (IVUS) and virtual histology.

"Abbott's bioabsorbable stent may be a major breakthrough in the treatment of narrowed coronary arteries. The two-year ABSORB trial results show that the bioabsorbable device did its job of relieving coronary obstructions and preventing re-narrowing, and that it did this safely," said John Ormiston, M.D., medical director at Mercy Hospital in Auckland, New Zealand and principal investigator in the first phase of the ABSORB trial. "With no rigid stent remaining, vasomotion - the natural movement of the artery - was restored, and the artery appeared to behave like a normal artery. Who would want a permanent device if a temporary one may do the job and then disappear?"

Abbott is the only company with long-term clinical
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
4. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
7. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
8. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
9. SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa
10. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
11. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 29, 2014 Electrodes ... potential which can be amplified to diagnose as ... electrodes used in medical devices facilitate the detection ... from muscle cells and neurons of the patients. ... utilize the radiofrequency alternating current to perform minimally ...
(Date:10/30/2014)... Oct. 29, 2014 Hospital stretchers are ... location to another, inside or outside of medical ... stretchers are also used for several specialized functions ... and emergency platforms. The hospital stretchers ... as future market potential of hospital stretchers globally. ...
(Date:10/30/2014)... 2014 Today Eli Lilly and Company (NYSE: ... technology transfer program to increase the global supply of ... effort included Lilly donating manufacturing technology and know-how for ... , India , ... – all MDR-TB ,hot spots., It also served ...
Breaking Medicine Technology:Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4
... , LAKE FOREST, Ill. , Jan. 12 ... of injectable pharmaceuticals announced today the launch of Ibutilide ... from Pfizer Inc. , (Logo:   http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO ) , ... Pharma,s continued growth and dedication to a consistently expanding ...
... Jan. 12 CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of approximately 15%, to 8.75 cents per share on ... holders of record on January 22, 2010 . This increase translates into ... cents per share from the previous rate of 30.5 cents . ...
Cached Medicine Technology:Bioniche Pharma Launches Ibutilide Fumarate Injection 2CVS Caremark Corporation Increases Quarterly Dividend 15% 2
(Date:10/30/2014)... New Haven, CT (PRWEB) October 30, 2014 ... product categories are raising questions about the impact of ... as the marketing method most likely to influence a ... online research poll of 525 consumers conducted by radio ... in four product categories, isolating the results of respondents ...
(Date:10/30/2014)... Thompson HealthDay Reporter WEDNESDAY, ... Liberia -- one of three West African nations ravaged by ... said Wednesday. Dr. Bruce Aylward, WHO,s assistant director general, ... in Liberia and no increase in laboratory-confirmed cases. He said ... the epidemic may be making some progress, The New ...
(Date:10/30/2014)... Horse Sense & Sensitivity (HSS), ... needs individuals in the Jacksonville area, will be holding ... 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates Road). ... and is designed to raise awareness and funds to ... Round-Up is free. Ticket purchases will be required for ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 REV'D Provision ... are now available through a unique service called, ... designed to empower the everyday athlete. The Feed has ... athletes and created a system to pass that information ... see REV’D® is now available on The Feed!” says ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Victory ... today its 2014 third quarter infection rates and ... boasted infection rates of only two percent or ... satisfaction scores exceeding 98 percent. , “We are ... which included rising satisfaction scores,” said Robert Helms, ...
Breaking Medicine News(10 mins):Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3
... impoverished 70-year-old man and his three physically challenged sons have ... saying there seemed to be little hope for the family. ... is probably a wise option," says 70-year-old Hakimuddin, a resident ... sons, Raffiuddin, 35, Mayiuddin, 33, and Mustaffa, 30, are stated ...
... transplantation is quite young, substantial advancements and success have led ... the demand for them. The United Network for Organ Sharing ... based primarily on wait time, sensitization and HLA matching. ... to the person at the top of the national list. ...
... is a new innovation in treating severe and complex wounds ... dressing changes. A new study in Wound Repair and Regeneration ... with children, and can be life-saving. ,“This wound ... negative suction pressure to the wound base through a sponge ...
... Britons may just feel the heart in their mouth when they ... of suffering a heart attack// have finally been identified by scientists. ... that one fifth of Britons carry a particular gene which doubles ... could come in the form of making healthy lifestyle choices that ...
... study in The American Journal of Gastroenterology suggests that ... is attacked in those// who suffer from Crohn’s disease. ... patient will eventually require surgical treatment. ,“In ... frequently in the small intestine, rather than the colon,” ...
... Delhi: The common cold may cause uncommon ailments if neglected, ... cold because we have always thought it is harmless. But ... untreated. It could also negatively impact vision or cause harm ... a surge in cases of chronic sinusitis because of unchecked ...
Cached Medicine News:Health News:70-year-old, Three Sons Seek Mercy Death 2Health News:Who Receives a Kidney Transplant First? 2Health News:The DNA That Spells Double Risk of Heart Attack 2Health News:A Cold Shoulder to Cold - At Your Risk 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: